title: [Clinical evaluation of cefbuperazone in severe infections complicated with hematological disorders].
abstract: The efficacy and the safety of an antibiotic in cephamycin group, cefbuperazone (CBPZ), were investigated in 93 patients with severe infections complicated with hematological disorders. The efficacy evaluation was made in 85 cases with underlying hematological disorders including 49 cases (57.6%) of leukemia and 18 cases (21.2%) of malignant lymphoma. The overall efficacy rate was 50.6% of the 85 evaluable cases. The clinical efficacy rate for sepsis and suspected sepsis was 53.4%. The most frequently used group of antibiotics for combination therapy was aminoglycosides in 37 cases, in which an efficacy rate of 62.2%, a higher rate than the efficacy rate of 48.5% for all the combination therapy cases, was obtained. In 16 cases in which penicillins were used as combination drug, the efficacy rate obtained was low, 31.3%. Efficacy rates obtained for cases with different neutrophil counts at the start of therapies were as follows: 52.2% in 23 cases with neutrophil counts below 100/mm3, 46.2% in 13 cases with neutrophil counts between 100 and 499/mm3 and 51.3% in 39 cases with neutrophil counts equal to or above 500/mm3, thus no significant differences in efficacy rates were observed for patients with different neutrophil counts. These results appear to suggest that CBPZ, alone or in combination with other antibiotic such as aminoglycosides, may be quite useful in the treatment of severe infections in patients with hematological disorders.
authors.affiliation: Department of Hematology, Social Insurance Chukyo Hospital.
authors.forename: H
authors.initials: H
authors.lastname: Mizuno
authors.forename: H
authors.initials: H
authors.lastname: Yamao
authors.forename: H
authors.initials: H
authors.lastname: Saito
authors.forename: R
authors.initials: R
authors.lastname: Ohno
authors.forename: T
authors.initials: T
authors.lastname: Hotta
authors.forename: K
authors.initials: K
authors.lastname: Ohnishi
authors.forename: T
authors.initials: T
authors.lastname: Murate
authors.forename: Y
authors.initials: Y
authors.lastname: Kagami
authors.forename: Y
authors.initials: Y
authors.lastname: Mitomo
authors.forename: M
authors.initials: M
authors.lastname: Nitta
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000583:Amikacin / Q000008:administration & dosage; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology; D002513:Cephamycins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002981:Clindamycin / Q000008:administration & dosage; D004359:Drug Therapy, Combination / Q000008:administration & dosage; D005260:Female; D005578:Fosfomycin / Q000008:administration & dosage; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D008297:Male
chemical_list: D002513:Cephamycins; D005578:Fosfomycin; D002981:Clindamycin; D000583:Amikacin; C035978:cefbuperazone